Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

BACKGROUND: AGITG DOCTOR was a randomised phase 2 trial of pre-operative cisplatin, 5 fluorouracil (CF) followed by docetaxel (D) with or without radiotherapy (RT) based on poor early response to CF, detected via PET, for resectable oesophageal adenocarcinoma. This study describes PROs over 2 years....

Descripción completa

Detalles Bibliográficos
Autores principales: Mercieca-Bebber, R., Barnes, E. H., Wilson, K., Samoon, Z., Walpole, E., Mai, T., Ackland, S., Burge, M., Dickie, G., Watson, D., Leung, J., Wang, T., Bohmer, R., Cameron, D., Simes, J., Gebski, V., Smithers, M., Thomas, J., Zalcberg, J., Barbour, A. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922838/
https://www.ncbi.nlm.nih.gov/pubmed/35291965
http://dx.doi.org/10.1186/s12885-022-09270-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922838/
https://www.ncbi.nlm.nih.gov/pubmed/35291965
http://dx.doi.org/10.1186/s12885-022-09270-4

Ejemplares similares